Role of ivermectin in patients hospitalized with COVID-19: a systematic review of literature.
Muhammad Waleed ChaudhrySyed Muhammad ZubairAli Bin Sarwar ZubairiMuhammad IrfanPublished in: Advances in respiratory medicine (2021)
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected almost every country in the world since De-cember 2019. Despite the efforts of the human race to combat the virus, we are still looking for an evidence-based permanent cure for the disease. Ivermectin has recently emerged as one of the therapies having a beneficial effect on COVID-19. Ivermectin, owing to its properties, continues to be a possible treatment against the COVID-19 disease. Already being a mainstream drug with minimal adverse effects, it garners valid consideration. It's use in hospitalized patients, randomized controlled trials, and observational studies has also supported its implementation. In this article, we have reviewed recent studies and explored the effectiveness of ivermectin in hospitalized COVID-19 patients.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- randomized controlled trial
- drug administration
- end stage renal disease
- ejection fraction
- endothelial cells
- chronic kidney disease
- quality improvement
- systematic review
- healthcare
- newly diagnosed
- primary care
- prognostic factors
- emergency department
- case control
- combination therapy
- electronic health record
- adverse drug
- patient reported
- meta analyses